Liver Cancer Diagnostics Market

TMR's report on the global Liver Cancer Diagnostics Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Liver Cancer Diagnostics Market for the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Liver Cancer Diagnostics Market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Global Liver Cancer Diagnostics Market.

Market Snapshot
Market Value in 2024	US$ 9.6 Bn
Market Value in 2035	US$ 18.4 Bn
CAGR	6.1%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the Global Liver Cancer Diagnostics Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the Global Liver Cancer Diagnostics Market. These serve as valuable tools for existing Market players as well as for entities interested in participating in the Global Liver Cancer Diagnostics Market .

The report delves into the competitive landscape of the Global Liver Cancer Diagnostics Market. Key players operating in the global Liver Cancer Diagnostics Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Liver Cancer Diagnostics Market profiled in this report.

Key Questions Answered in Global Liver Cancer Diagnostics Market Report:

What is the sales/revenue generated by Liver Cancer Diagnostics Market across all regions during the forecast period?
What are the opportunities in the global Liver Cancer Diagnostics Market?
What are the major drivers, restraints, opportunities, and threats in the Market?
Which regional Market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2035?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the Market positions of different companies operating in the global Market?

Global Liver Cancer Diagnostics Market - Research Objectives and Research Approach

The comprehensive report on the global Liver Cancer Diagnostics Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Liver Cancer Diagnostics Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market Share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the Liver Cancer Diagnostics Market.

Product Code: 61431

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Liver Cancer Diagnostics Market

4. Market Overview

4.1. Introduction
- 4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Liver Cancer Diagnostics Market Analysis and Forecast, 2020-2035
- 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

5.1. Healthcare Expenditure across Key Countries / Regions
5.2. Recent Advancements in Liver Cancer Diagnostics
5.3. Pricing Analysis of Liver Cancer Diagnostics
5.4. Regulatory Scenario across Key Regions / Countries
5.5. Reimbursement Landscape across Key Regions / Countries
5.6. PORTER's Five Forces Analysis
5.7. PESTLE Analysis
5.8. Go-to-Market Strategy for New Market Entrants
5.9. Key Purchase Metrics for End-users
5.10. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions)
5.11. Benchmarking of the Products Offered by the Leading Competitors

6. Global Liver Cancer Diagnostics Market Analysis and Forecast, by Diagnostic Test Type

6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 6.3.1. Imaging Tests
  - 6.3.1.1. Ultrasound
  - 6.3.1.2. Computed tomography (CT)
  - 6.3.1.3. Magnetic resonance imaging (MRI)
  - 6.3.1.4. Others
- 6.3.2. Blood tests
  - 6.3.2.1. Alpha-fetoprotein blood (AFP) test
  - 6.3.2.2. Liver function tests (LFTs)
  - 6.3.2.3. Blood clotting tests
  - 6.3.2.4. Others
- 6.3.3. Biopsy
  - 6.3.3.1. Needle biopsy
  - 6.3.3.2. Laparoscopic biopsy
  - 6.3.3.3. Surgical biopsy
- 6.3.4. Genetic Biomarkers
  - 6.3.4.1. miR-122 and miR-21
  - 6.3.4.2. TP53
  - 6.3.4.3. Other Genetic Biomarkers
6.4. Market Attractiveness Analysis, by Diagnostic Test Type

7. Global Liver Cancer Diagnostics Market Analysis and Forecast, by Cancer Type

7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Cancer Type, 2020-2035
- 7.3.1. Hepatocellular carcinoma (HCC)
- 7.3.2. Cholangiocarcinoma
- 7.3.3. Angiosarcoma of the liver
- 7.3.4. Others
7.4. Market Attractiveness Analysis, by Cancer Type

8. Global Liver Cancer Diagnostics Market Analysis and Forecast, by End-user

8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020-2035
- 8.3.1. Hospital Laboratories
- 8.3.2. Diagnostic Centers
- 8.3.3. Academic and Research Institutes
- 8.3.4. Others
8.4. Market Attractiveness Analysis, by End-user

9. Global Liver Cancer Diagnostics Market Analysis and Forecast, by Region

9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2035
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Liver Cancer Diagnostics Market Analysis and Forecast

10.1. Introduction
- 10.1.1. Key Findings
10.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 10.2.1. Imaging Tests
  - 10.2.1.1. Ultrasound
  - 10.2.1.2. Computed tomography (CT)
  - 10.2.1.3. Magnetic resonance imaging (MRI)
  - 10.2.1.4. Others
- 10.2.2. Blood tests
  - 10.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 10.2.2.2. Liver function tests (LFTs)
  - 10.2.2.3. Blood clotting tests
  - 10.2.2.4. Others
- 10.2.3. Biopsy
  - 10.2.3.1. Needle biopsy
  - 10.2.3.2. Laparoscopic biopsy
  - 10.2.3.3. Surgical biopsy
- 10.2.4. Genetic Biomarkers
  - 10.2.4.1. miR-122 and miR-21
  - 10.2.4.2. TP53
  - 10.2.4.3. Other Genetic Biomarkers
10.3. Market Value Forecast, by Cancer Type, 2020-2035
- 10.3.1. Hepatocellular carcinoma (HCC)
- 10.3.2. Cholangiocarcinoma
- 10.3.3. Angiosarcoma of the liver
- 10.3.4. Others
10.4. Market Value Forecast, by End-user, 2020-2035
- 10.4.1. Hospital Laboratories
- 10.4.2. Diagnostic Centers
- 10.4.3. Academic and Research Institutes
- 10.4.4. Others
10.5. Market Value Forecast, by Country, 2020-2035
- 10.5.1. U.S.
- 10.5.2. Canada
10.6. Market Attractiveness Analysis
- 10.6.1. By Diagnostic Test Type
- 10.6.2. By Cancer Type
- 10.6.3. By End-user
- 10.6.4. By Country

11. U.S. Liver Cancer Diagnostics Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 11.2.1. Imaging Tests
  - 11.2.1.1. Ultrasound
  - 11.2.1.2. Computed tomography (CT)
  - 11.2.1.3. Magnetic resonance imaging (MRI)
  - 11.2.1.4. Others
- 11.2.2. Blood tests
  - 11.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 11.2.2.2. Liver function tests (LFTs)
  - 11.2.2.3. Blood clotting tests
  - 11.2.2.4. Others
- 11.2.3. Biopsy
  - 11.2.3.1. Needle biopsy
  - 11.2.3.2. Laparoscopic biopsy
  - 11.2.3.3. Surgical biopsy
- 11.2.4. Genetic Biomarkers
  - 11.2.4.1. miR-122 and miR-21
  - 11.2.4.2. TP53
  - 11.2.4.3. Other Genetic Biomarkers
11.3. Market Value Forecast, by Cancer Type, 2020-2035
- 11.3.1. Hepatocellular carcinoma (HCC)
- 11.3.2. Cholangiocarcinoma
- 11.3.3. Angiosarcoma of the liver
- 11.3.4. Others
11.4. Market Value Forecast, by End-user, 2020-2035
- 11.4.1. Hospital Laboratories
- 11.4.2. Diagnostic Centers
- 11.4.3. Academic and Research Institutes
- 11.4.4. Others
11.5. Market Attractiveness Analysis
- 11.5.1. By Diagnostic Test Type
- 11.5.2. By Cancer Type
- 11.5.3. By End-user

12. Canada Liver Cancer Diagnostics Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 12.2.1. Imaging Tests
  - 12.2.1.1. Ultrasound
  - 12.2.1.2. Computed tomography (CT)
  - 12.2.1.3. Magnetic resonance imaging (MRI)
  - 12.2.1.4. Others
- 12.2.2. Blood tests
  - 12.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 12.2.2.2. Liver function tests (LFTs)
  - 12.2.2.3. Blood clotting tests
  - 12.2.2.4. Others
- 12.2.3. Biopsy
  - 12.2.3.1. Needle biopsy
  - 12.2.3.2. Laparoscopic biopsy
  - 12.2.3.3. Surgical biopsy
- 12.2.4. Genetic Biomarkers
  - 12.2.4.1. miR-122 and miR-21
  - 12.2.4.2. TP53
  - 12.2.4.3. Other Genetic Biomarkers
12.3. Market Value Forecast, by Cancer Type, 2020-2035
- 12.3.1. Hepatocellular carcinoma (HCC)
- 12.3.2. Cholangiocarcinoma
- 12.3.3. Angiosarcoma of the liver
- 12.3.4. Others
12.4. Market Value Forecast, by End-user, 2020-2035
- 12.4.1. Hospital Laboratories
- 12.4.2. Diagnostic Centers
- 12.4.3. Academic and Research Institutes
- 12.4.4. Others
12.5. Market Attractiveness Analysis
- 12.5.1. By Diagnostic Test Type
- 12.5.2. By Cancer Type
- 12.5.3. By End-user

13. Europe Liver Cancer Diagnostics Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 13.2.1. Imaging Tests
  - 13.2.1.1. Ultrasound
  - 13.2.1.2. Computed tomography (CT)
  - 13.2.1.3. Magnetic resonance imaging (MRI)
  - 13.2.1.4. Others
- 13.2.2. Blood tests
  - 13.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 13.2.2.2. Liver function tests (LFTs)
  - 13.2.2.3. Blood clotting tests
  - 13.2.2.4. Others
- 13.2.3. Biopsy
  - 13.2.3.1. Needle biopsy
  - 13.2.3.2. Laparoscopic biopsy
  - 13.2.3.3. Surgical biopsy
- 13.2.4. Genetic Biomarkers
  - 13.2.4.1. miR-122 and miR-21
  - 13.2.4.2. TP53
  - 13.2.4.3. Other Genetic Biomarkers
13.3. Market Value Forecast, by Cancer Type, 2020-2035
- 13.3.1. Hepatocellular carcinoma (HCC)
- 13.3.2. Cholangiocarcinoma
- 13.3.3. Angiosarcoma of the liver
- 13.3.4. Others
13.4. Market Value Forecast, by End-user, 2020-2035
- 13.4.1. Hospital Laboratories
- 13.4.2. Diagnostic Centers
- 13.4.3. Academic and Research Institutes
- 13.4.4. Others
13.5. Market Value Forecast, by Country/Sub-region, 2020-2035
- 13.5.1. Germany
- 13.5.2. UK
- 13.5.3. France
- 13.5.4. Italy
- 13.5.5. Spain
- 13.5.6. The Netherlands
- 13.5.7. Rest of Europe
13.6. Market Attractiveness Analysis
- 13.6.1. By Diagnostic Test Type
- 13.6.2. By Cancer Type
- 13.6.3. By End-user
- 13.6.4. By Country/Sub-region

14. Germany Liver Cancer Diagnostics Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 14.2.1. Imaging Tests
  - 14.2.1.1. Ultrasound
  - 14.2.1.2. Computed tomography (CT)
  - 14.2.1.3. Magnetic resonance imaging (MRI)
  - 14.2.1.4. Others
- 14.2.2. Blood tests
  - 14.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 14.2.2.2. Liver function tests (LFTs)
  - 14.2.2.3. Blood clotting tests
  - 14.2.2.4. Others
- 14.2.3. Biopsy
  - 14.2.3.1. Needle biopsy
  - 14.2.3.2. Laparoscopic biopsy
  - 14.2.3.3. Surgical biopsy
- 14.2.4. Genetic Biomarkers
  - 14.2.4.1. miR-122 and miR-21
  - 14.2.4.2. TP53
  - 14.2.4.3. Other Genetic Biomarkers
14.3. Market Value Forecast, by Cancer Type, 2020-2035
- 14.3.1. Hepatocellular carcinoma (HCC)
- 14.3.2. Cholangiocarcinoma
- 14.3.3. Angiosarcoma of the liver
- 14.3.4. Others
14.4. Market Value Forecast, by End-user, 2020-2035
- 14.4.1. Hospital Laboratories
- 14.4.2. Diagnostic Centers
- 14.4.3. Academic and Research Institutes
- 14.4.4. Others
14.5. Market Attractiveness Analysis
- 14.5.1. By Diagnostic Test Type
- 14.5.2. By Cancer Type
- 14.5.3. By End-user

15. UK Liver Cancer Diagnostics Market Analysis and Forecast

15.1. Introduction
- 15.1.1. Key Findings
15.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 15.2.1. Imaging Tests
  - 15.2.1.1. Ultrasound
  - 15.2.1.2. Computed tomography (CT)
  - 15.2.1.3. Magnetic resonance imaging (MRI)
  - 15.2.1.4. Others
- 15.2.2. Blood tests
  - 15.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 15.2.2.2. Liver function tests (LFTs)
  - 15.2.2.3. Blood clotting tests
  - 15.2.2.4. Others
- 15.2.3. Biopsy
  - 15.2.3.1. Needle biopsy
  - 15.2.3.2. Laparoscopic biopsy
  - 15.2.3.3. Surgical biopsy
- 15.2.4. Genetic Biomarkers
  - 15.2.4.1. miR-122 and miR-21
  - 15.2.4.2. TP53
  - 15.2.4.3. Other Genetic Biomarkers
15.3. Market Value Forecast, by Cancer Type, 2020-2035
- 15.3.1. Hepatocellular carcinoma (HCC)
- 15.3.2. Cholangiocarcinoma
- 15.3.3. Angiosarcoma of the liver
- 15.3.4. Others
15.4. Market Value Forecast, by End-user, 2020-2035
- 15.4.1. Hospital Laboratories
- 15.4.2. Diagnostic Centers
- 15.4.3. Academic and Research Institutes
- 15.4.4. Others
15.5. Market Attractiveness Analysis
- 15.5.1. By Diagnostic Test Type
- 15.5.2. By Cancer Type
- 15.5.3. By End-user

16. France Liver Cancer Diagnostics Market Analysis and Forecast

16.1. Introduction
- 16.1.1. Key Findings
16.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 16.2.1. Imaging Tests
  - 16.2.1.1. Ultrasound
  - 16.2.1.2. Computed tomography (CT)
  - 16.2.1.3. Magnetic resonance imaging (MRI)
  - 16.2.1.4. Others
- 16.2.2. Blood tests
  - 16.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 16.2.2.2. Liver function tests (LFTs)
  - 16.2.2.3. Blood clotting tests
  - 16.2.2.4. Others
- 16.2.3. Biopsy
  - 16.2.3.1. Needle biopsy
  - 16.2.3.2. Laparoscopic biopsy
  - 16.2.3.3. Surgical biopsy
- 16.2.4. Genetic Biomarkers
  - 16.2.4.1. miR-122 and miR-21
  - 16.2.4.2. TP53
  - 16.2.4.3. Other Genetic Biomarkers
16.3. Market Value Forecast, by Cancer Type, 2020-2035
- 16.3.1. Hepatocellular carcinoma (HCC)
- 16.3.2. Cholangiocarcinoma
- 16.3.3. Angiosarcoma of the liver
- 16.3.4. Others
16.4. Market Value Forecast, by End-user, 2020-2035
- 16.4.1. Hospital Laboratories
- 16.4.2. Diagnostic Centers
- 16.4.3. Academic and Research Institutes
- 16.4.4. Others
16.5. Market Attractiveness Analysis
- 16.5.1. By Diagnostic Test Type
- 16.5.2. By Cancer Type
- 16.5.3. By End-user

17. Italy Liver Cancer Diagnostics Market Analysis and Forecast

17.1. Introduction
- 17.1.1. Key Findings
17.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 17.2.1. Imaging Tests
  - 17.2.1.1. Ultrasound
  - 17.2.1.2. Computed tomography (CT)
  - 17.2.1.3. Magnetic resonance imaging (MRI)
  - 17.2.1.4. Others
- 17.2.2. Blood tests
  - 17.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 17.2.2.2. Liver function tests (LFTs)
  - 17.2.2.3. Blood clotting tests
  - 17.2.2.4. Others
- 17.2.3. Biopsy
  - 17.2.3.1. Needle biopsy
  - 17.2.3.2. Laparoscopic biopsy
  - 17.2.3.3. Surgical biopsy
- 17.2.4. Genetic Biomarkers
  - 17.2.4.1. miR-122 and miR-21
  - 17.2.4.2. TP53
  - 17.2.4.3. Other Genetic Biomarkers
17.3. Market Value Forecast, by Cancer Type, 2020-2035
- 17.3.1. Hepatocellular carcinoma (HCC)
- 17.3.2. Cholangiocarcinoma
- 17.3.3. Angiosarcoma of the liver
- 17.3.4. Others
17.4. Market Value Forecast, by End-user, 2020-2035
- 17.4.1. Hospital Laboratories
- 17.4.2. Diagnostic Centers
- 17.4.3. Academic and Research Institutes
- 17.4.4. Others
17.5. Market Attractiveness Analysis
- 17.5.1. By Diagnostic Test Type
- 17.5.2. By Cancer Type
- 17.5.3. By End-user

18. Spain Liver Cancer Diagnostics Market Analysis and Forecast

18.1. Introduction
- 18.1.1. Key Findings
18.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 18.2.1. Imaging Tests
  - 18.2.1.1. Ultrasound
  - 18.2.1.2. Computed tomography (CT)
  - 18.2.1.3. Magnetic resonance imaging (MRI)
  - 18.2.1.4. Others
- 18.2.2. Blood tests
  - 18.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 18.2.2.2. Liver function tests (LFTs)
  - 18.2.2.3. Blood clotting tests
  - 18.2.2.4. Others
- 18.2.3. Biopsy
  - 18.2.3.1. Needle biopsy
  - 18.2.3.2. Laparoscopic biopsy
  - 18.2.3.3. Surgical biopsy
- 18.2.4. Genetic Biomarkers
  - 18.2.4.1. miR-122 and miR-21
  - 18.2.4.2. TP53
  - 18.2.4.3. Other Genetic Biomarkers
18.3. Market Value Forecast, by Cancer Type, 2020-2035
- 18.3.1. Hepatocellular carcinoma (HCC)
- 18.3.2. Cholangiocarcinoma
- 18.3.3. Angiosarcoma of the liver
- 18.3.4. Others
18.4. Market Value Forecast, by End-user, 2020-2035
- 18.4.1. Hospital Laboratories
- 18.4.2. Diagnostic Centers
- 18.4.3. Academic and Research Institutes
- 18.4.4. Others
18.5. Market Attractiveness Analysis
- 18.5.1. By Diagnostic Test Type
- 18.5.2. By Cancer Type
- 18.5.3. By End-user

19. The Netherlands Liver Cancer Diagnostics Market Analysis and Forecast

19.1. Introduction
- 19.1.1. Key Findings
19.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 19.2.1. Imaging Tests
  - 19.2.1.1. Ultrasound
  - 19.2.1.2. Computed tomography (CT)
  - 19.2.1.3. Magnetic resonance imaging (MRI)
  - 19.2.1.4. Others
- 19.2.2. Blood tests
  - 19.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 19.2.2.2. Liver function tests (LFTs)
  - 19.2.2.3. Blood clotting tests
  - 19.2.2.4. Others
- 19.2.3. Biopsy
  - 19.2.3.1. Needle biopsy
  - 19.2.3.2. Laparoscopic biopsy
  - 19.2.3.3. Surgical biopsy
- 19.2.4. Genetic Biomarkers
  - 19.2.4.1. miR-122 and miR-21
  - 19.2.4.2. TP53
  - 19.2.4.3. Other Genetic Biomarkers
19.3. Market Value Forecast, by Cancer Type, 2020-2035
- 19.3.1. Hepatocellular carcinoma (HCC)
- 19.3.2. Cholangiocarcinoma
- 19.3.3. Angiosarcoma of the liver
- 19.3.4. Others
19.4. Market Value Forecast, by End-user, 2020-2035
- 19.4.1. Hospital Laboratories
- 19.4.2. Diagnostic Centers
- 19.4.3. Academic and Research Institutes
- 19.4.4. Others
19.5. Market Attractiveness Analysis
- 19.5.1. By Diagnostic Test Type
- 19.5.2. By Cancer Type
- 19.5.3. By End-user

20. Rest of Europe Liver Cancer Diagnostics Market Analysis and Forecast

20.1. Introduction
- 20.1.1. Key Findings
20.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 20.2.1. Imaging Tests
  - 20.2.1.1. Ultrasound
  - 20.2.1.2. Computed tomography (CT)
  - 20.2.1.3. Magnetic resonance imaging (MRI)
  - 20.2.1.4. Others
- 20.2.2. Blood tests
  - 20.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 20.2.2.2. Liver function tests (LFTs)
  - 20.2.2.3. Blood clotting tests
  - 20.2.2.4. Others
- 20.2.3. Biopsy
  - 20.2.3.1. Needle biopsy
  - 20.2.3.2. Laparoscopic biopsy
  - 20.2.3.3. Surgical biopsy
- 20.2.4. Genetic Biomarkers
  - 20.2.4.1. miR-122 and miR-21
  - 20.2.4.2. TP53
  - 20.2.4.3. Other Genetic Biomarkers
20.3. Market Value Forecast, by Cancer Type, 2020-2035
- 20.3.1. Hepatocellular carcinoma (HCC)
- 20.3.2. Cholangiocarcinoma
- 20.3.3. Angiosarcoma of the liver
- 20.3.4. Others
20.4. Market Value Forecast, by End-user, 2020-2035
- 20.4.1. Hospital Laboratories
- 20.4.2. Diagnostic Centers
- 20.4.3. Academic and Research Institutes
- 20.4.4. Others
20.5. Market Attractiveness Analysis
- 20.5.1. By Diagnostic Test Type
- 20.5.2. By Cancer Type
- 20.5.3. By End-user

21. Asia Pacific Liver Cancer Diagnostics Market Analysis and Forecast

21.1. Introduction
- 21.1.1. Key Findings
21.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 21.2.1. Imaging Tests
  - 21.2.1.1. Ultrasound
  - 21.2.1.2. Computed tomography (CT)
  - 21.2.1.3. Magnetic resonance imaging (MRI)
  - 21.2.1.4. Others
- 21.2.2. Blood tests
  - 21.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 21.2.2.2. Liver function tests (LFTs)
  - 21.2.2.3. Blood clotting tests
  - 21.2.2.4. Others
- 21.2.3. Biopsy
  - 21.2.3.1. Needle biopsy
  - 21.2.3.2. Laparoscopic biopsy
  - 21.2.3.3. Surgical biopsy
- 21.2.4. Genetic Biomarkers
  - 21.2.4.1. miR-122 and miR-21
  - 21.2.4.2. TP53
  - 21.2.4.3. Other Genetic Biomarkers
21.3. Market Value Forecast, by Cancer Type, 2020-2035
- 21.3.1. Hepatocellular carcinoma (HCC)
- 21.3.2. Cholangiocarcinoma
- 21.3.3. Angiosarcoma of the liver
- 21.3.4. Others
21.4. Market Value Forecast, by End-user, 2020-2035
- 21.4.1. Hospital Laboratories
- 21.4.2. Diagnostic Centers
- 21.4.3. Academic and Research Institutes
- 21.4.4. Others
21.5. Market Value Forecast, by Country/Sub-region, 2020-2035
- 21.5.1. China
- 21.5.2. India
- 21.5.3. Japan
- 21.5.4. South Korea
- 21.5.5. Australia & New Zealand
- 21.5.6. ASEAN
- 21.5.7. Rest of Asia Pacific
21.6. Market Attractiveness Analysis
- 21.6.1. By Diagnostic Test Type
- 21.6.2. By Cancer Type
- 21.6.3. By End-user
- 21.6.4. By Country/Sub-region

22. China Liver Cancer Diagnostics Market Analysis and Forecast

22.1. Introduction
- 22.1.1. Key Findings
22.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 22.2.1. Imaging Tests
  - 22.2.1.1. Ultrasound
  - 22.2.1.2. Computed tomography (CT)
  - 22.2.1.3. Magnetic resonance imaging (MRI)
  - 22.2.1.4. Others
- 22.2.2. Blood tests
  - 22.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 22.2.2.2. Liver function tests (LFTs)
  - 22.2.2.3. Blood clotting tests
  - 22.2.2.4. Others
- 22.2.3. Biopsy
  - 22.2.3.1. Needle biopsy
  - 22.2.3.2. Laparoscopic biopsy
  - 22.2.3.3. Surgical biopsy
- 22.2.4. Genetic Biomarkers
  - 22.2.4.1. miR-122 and miR-21
  - 22.2.4.2. TP53
  - 22.2.4.3. Other Genetic Biomarkers
22.3. Market Value Forecast, by Cancer Type, 2020-2035
- 22.3.1. Hepatocellular carcinoma (HCC)
- 22.3.2. Cholangiocarcinoma
- 22.3.3. Angiosarcoma of the liver
- 22.3.4. Others
22.4. Market Value Forecast, by End-user, 2020-2035
- 22.4.1. Hospital Laboratories
- 22.4.2. Diagnostic Centers
- 22.4.3. Academic and Research Institutes
- 22.4.4. Others
22.5. Market Attractiveness Analysis
- 22.5.1. By Diagnostic Test Type
- 22.5.2. By Cancer Type
- 22.5.3. By End-user

23. India Liver Cancer Diagnostics Market Analysis and Forecast

23.1. Introduction
- 23.1.1. Key Findings
23.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 23.2.1. Imaging Tests
  - 23.2.1.1. Ultrasound
  - 23.2.1.2. Computed tomography (CT)
  - 23.2.1.3. Magnetic resonance imaging (MRI)
  - 23.2.1.4. Others
- 23.2.2. Blood tests
  - 23.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 23.2.2.2. Liver function tests (LFTs)
  - 23.2.2.3. Blood clotting tests
  - 23.2.2.4. Others
- 23.2.3. Biopsy
  - 23.2.3.1. Needle biopsy
  - 23.2.3.2. Laparoscopic biopsy
  - 23.2.3.3. Surgical biopsy
- 23.2.4. Genetic Biomarkers
  - 23.2.4.1. miR-122 and miR-21
  - 23.2.4.2. TP53
  - 23.2.4.3. Other Genetic Biomarkers
23.3. Market Value Forecast, by Cancer Type, 2020-2035
- 23.3.1. Hepatocellular carcinoma (HCC)
- 23.3.2. Cholangiocarcinoma
- 23.3.3. Angiosarcoma of the liver
- 23.3.4. Others
23.4. Market Value Forecast, by End-user, 2020-2035
- 23.4.1. Hospital Laboratories
- 23.4.2. Diagnostic Centers
- 23.4.3. Academic and Research Institutes
- 23.4.4. Others
23.5. Market Attractiveness Analysis
- 23.5.1. By Diagnostic Test Type
- 23.5.2. By Cancer Type
- 23.5.3. By End-user

24. Japan Liver Cancer Diagnostics Market Analysis and Forecast

24.1. Introduction
- 24.1.1. Key Findings
24.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 24.2.1. Imaging Tests
  - 24.2.1.1. Ultrasound
  - 24.2.1.2. Computed tomography (CT)
  - 24.2.1.3. Magnetic resonance imaging (MRI)
  - 24.2.1.4. Others
- 24.2.2. Blood tests
  - 24.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 24.2.2.2. Liver function tests (LFTs)
  - 24.2.2.3. Blood clotting tests
  - 24.2.2.4. Others
- 24.2.3. Biopsy
  - 24.2.3.1. Needle biopsy
  - 24.2.3.2. Laparoscopic biopsy
  - 24.2.3.3. Surgical biopsy
- 24.2.4. Genetic Biomarkers
  - 24.2.4.1. miR-122 and miR-21
  - 24.2.4.2. TP53
  - 24.2.4.3. Other Genetic Biomarkers
24.3. Market Value Forecast, by Cancer Type, 2020-2035
- 24.3.1. Hepatocellular carcinoma (HCC)
- 24.3.2. Cholangiocarcinoma
- 24.3.3. Angiosarcoma of the liver
- 24.3.4. Others
24.4. Market Value Forecast, by End-user, 2020-2035
- 24.4.1. Hospital Laboratories
- 24.4.2. Diagnostic Centers
- 24.4.3. Academic and Research Institutes
- 24.4.4. Others
24.5. Market Attractiveness Analysis
- 24.5.1. By Diagnostic Test Type
- 24.5.2. By Cancer Type
- 24.5.3. By End-user

25. South Korea Liver Cancer Diagnostics Market Analysis and Forecast

25.1. Introduction
- 25.1.1. Key Findings
25.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 25.2.1. Imaging Tests
  - 25.2.1.1. Ultrasound
  - 25.2.1.2. Computed tomography (CT)
  - 25.2.1.3. Magnetic resonance imaging (MRI)
  - 25.2.1.4. Others
- 25.2.2. Blood tests
  - 25.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 25.2.2.2. Liver function tests (LFTs)
  - 25.2.2.3. Blood clotting tests
  - 25.2.2.4. Others
- 25.2.3. Biopsy
  - 25.2.3.1. Needle biopsy
  - 25.2.3.2. Laparoscopic biopsy
  - 25.2.3.3. Surgical biopsy
- 25.2.4. Genetic Biomarkers
  - 25.2.4.1. miR-122 and miR-21
  - 25.2.4.2. TP53
  - 25.2.4.3. Other Genetic Biomarkers
25.3. Market Value Forecast, by Cancer Type, 2020-2035
- 25.3.1. Hepatocellular carcinoma (HCC)
- 25.3.2. Cholangiocarcinoma
- 25.3.3. Angiosarcoma of the liver
- 25.3.4. Others
25.4. Market Value Forecast, by End-user, 2020-2035
- 25.4.1. Hospital Laboratories
- 25.4.2. Diagnostic Centers
- 25.4.3. Academic and Research Institutes
- 25.4.4. Others
25.5. Market Attractiveness Analysis
- 25.5.1. By Diagnostic Test Type
- 25.5.2. By Cancer Type
- 25.5.3. By End-user

26. Australia & New Zealand Liver Cancer Diagnostics Market Analysis and Forecast

26.1. Introduction
- 26.1.1. Key Findings
26.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 26.2.1. Imaging Tests
  - 26.2.1.1. Ultrasound
  - 26.2.1.2. Computed tomography (CT)
  - 26.2.1.3. Magnetic resonance imaging (MRI)
  - 26.2.1.4. Others
- 26.2.2. Blood tests
  - 26.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 26.2.2.2. Liver function tests (LFTs)
  - 26.2.2.3. Blood clotting tests
  - 26.2.2.4. Others
- 26.2.3. Biopsy
  - 26.2.3.1. Needle biopsy
  - 26.2.3.2. Laparoscopic biopsy
  - 26.2.3.3. Surgical biopsy
- 26.2.4. Genetic Biomarkers
  - 26.2.4.1. miR-122 and miR-21
  - 26.2.4.2. TP53
  - 26.2.4.3. Other Genetic Biomarkers
26.3. Market Value Forecast, by Cancer Type, 2020-2035
- 26.3.1. Hepatocellular carcinoma (HCC)
- 26.3.2. Cholangiocarcinoma
- 26.3.3. Angiosarcoma of the liver
- 26.3.4. Others
26.4. Market Value Forecast, by End-user, 2020-2035
- 26.4.1. Hospital Laboratories
- 26.4.2. Diagnostic Centers
- 26.4.3. Academic and Research Institutes
- 26.4.4. Others
26.5. Market Attractiveness Analysis
- 26.5.1. By Diagnostic Test Type
- 26.5.2. By Cancer Type
- 26.5.3. By End-user

27. ASEAN Liver Cancer Diagnostics Market Analysis and Forecast

27.1. Introduction
- 27.1.1. Key Findings
27.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 27.2.1. Imaging Tests
  - 27.2.1.1. Ultrasound
  - 27.2.1.2. Computed tomography (CT)
  - 27.2.1.3. Magnetic resonance imaging (MRI)
  - 27.2.1.4. Others
- 27.2.2. Blood tests
  - 27.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 27.2.2.2. Liver function tests (LFTs)
  - 27.2.2.3. Blood clotting tests
  - 27.2.2.4. Others
- 27.2.3. Biopsy
  - 27.2.3.1. Needle biopsy
  - 27.2.3.2. Laparoscopic biopsy
  - 27.2.3.3. Surgical biopsy
- 27.2.4. Genetic Biomarkers
  - 27.2.4.1. miR-122 and miR-21
  - 27.2.4.2. TP53
  - 27.2.4.3. Other Genetic Biomarkers
27.3. Market Value Forecast, by Cancer Type, 2020-2035
- 27.3.1. Hepatocellular carcinoma (HCC)
- 27.3.2. Cholangiocarcinoma
- 27.3.3. Angiosarcoma of the liver
- 27.3.4. Others
27.4. Market Value Forecast, by End-user, 2020-2035
- 27.4.1. Hospital Laboratories
- 27.4.2. Diagnostic Centers
- 27.4.3. Academic and Research Institutes
- 27.4.4. Others
27.5. Market Attractiveness Analysis
- 27.5.1. By Diagnostic Test Type
- 27.5.2. By Cancer Type
- 27.5.3. By End-user

28. Rest of Asia Pacific Liver Cancer Diagnostics Market Analysis and Forecast

28.1. Introduction
- 28.1.1. Key Findings
28.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 28.2.1. Imaging Tests
  - 28.2.1.1. Ultrasound
  - 28.2.1.2. Computed tomography (CT)
  - 28.2.1.3. Magnetic resonance imaging (MRI)
  - 28.2.1.4. Others
- 28.2.2. Blood tests
  - 28.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 28.2.2.2. Liver function tests (LFTs)
  - 28.2.2.3. Blood clotting tests
  - 28.2.2.4. Others
- 28.2.3. Biopsy
  - 28.2.3.1. Needle biopsy
  - 28.2.3.2. Laparoscopic biopsy
  - 28.2.3.3. Surgical biopsy
- 28.2.4. Genetic Biomarkers
  - 28.2.4.1. miR-122 and miR-21
  - 28.2.4.2. TP53
  - 28.2.4.3. Other Genetic Biomarkers
28.3. Market Value Forecast, by Cancer Type, 2020-2035
- 28.3.1. Hepatocellular carcinoma (HCC)
- 28.3.2. Cholangiocarcinoma
- 28.3.3. Angiosarcoma of the liver
- 28.3.4. Others
28.4. Market Value Forecast, by End-user, 2020-2035
- 28.4.1. Hospital Laboratories
- 28.4.2. Diagnostic Centers
- 28.4.3. Academic and Research Institutes
- 28.4.4. Others
28.5. Market Attractiveness Analysis
- 28.5.1. By Diagnostic Test Type
- 28.5.2. By Cancer Type
- 28.5.3. By End-user

29. Latin America Liver Cancer Diagnostics Market Analysis and Forecast

29.1. Introduction
- 29.1.1. Key Findings
29.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 29.2.1. Imaging Tests
  - 29.2.1.1. Ultrasound
  - 29.2.1.2. Computed tomography (CT)
  - 29.2.1.3. Magnetic resonance imaging (MRI)
  - 29.2.1.4. Others
- 29.2.2. Blood tests
  - 29.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 29.2.2.2. Liver function tests (LFTs)
  - 29.2.2.3. Blood clotting tests
  - 29.2.2.4. Others
- 29.2.3. Biopsy
  - 29.2.3.1. Needle biopsy
  - 29.2.3.2. Laparoscopic biopsy
  - 29.2.3.3. Surgical biopsy
- 29.2.4. Genetic Biomarkers
  - 29.2.4.1. miR-122 and miR-21
  - 29.2.4.2. TP53
  - 29.2.4.3. Other Genetic Biomarkers
29.3. Market Value Forecast, by Cancer Type, 2020-2035
- 29.3.1. Hepatocellular carcinoma (HCC)
- 29.3.2. Cholangiocarcinoma
- 29.3.3. Angiosarcoma of the liver
- 29.3.4. Others
29.4. Market Value Forecast, by End-user, 2020-2035
- 29.4.1. Hospital Laboratories
- 29.4.2. Diagnostic Centers
- 29.4.3. Academic and Research Institutes
- 29.4.4. Others
29.5. Market Value Forecast, by Country/Sub-region, 2020-2035
- 29.5.1. Brazil
- 29.5.2. Argentina
- 29.5.3. Mexico
- 29.5.4. Rest of Latin America
29.6. Market Attractiveness Analysis
- 29.6.1. By Diagnostic Test Type
- 29.6.2. By Cancer Type
- 29.6.3. By End-user
- 29.6.4. By Country/Sub-region

30. Brazil Liver Cancer Diagnostics Market Analysis and Forecast

30.1. Introduction
- 30.1.1. Key Findings
30.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 30.2.1. Imaging Tests
  - 30.2.1.1. Ultrasound
  - 30.2.1.2. Computed tomography (CT)
  - 30.2.1.3. Magnetic resonance imaging (MRI)
  - 30.2.1.4. Others
- 30.2.2. Blood tests
  - 30.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 30.2.2.2. Liver function tests (LFTs)
  - 30.2.2.3. Blood clotting tests
  - 30.2.2.4. Others
- 30.2.3. Biopsy
  - 30.2.3.1. Needle biopsy
  - 30.2.3.2. Laparoscopic biopsy
  - 30.2.3.3. Surgical biopsy
- 30.2.4. Genetic Biomarkers
  - 30.2.4.1. miR-122 and miR-21
  - 30.2.4.2. TP53
  - 30.2.4.3. Other Genetic Biomarkers
30.3. Market Value Forecast, by Cancer Type, 2020-2035
- 30.3.1. Hepatocellular carcinoma (HCC)
- 30.3.2. Cholangiocarcinoma
- 30.3.3. Angiosarcoma of the liver
- 30.3.4. Others
30.4. Market Value Forecast, by End-user, 2020-2035
- 30.4.1. Hospital Laboratories
- 30.4.2. Diagnostic Centers
- 30.4.3. Academic and Research Institutes
- 30.4.4. Others
30.5. Market Attractiveness Analysis
- 30.5.1. By Diagnostic Test Type
- 30.5.2. By Cancer Type
- 30.5.3. By End-user

31. Argentina Liver Cancer Diagnostics Market Analysis and Forecast

31.1. Introduction
- 31.1.1. Key Findings
31.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 31.2.1. Imaging Tests
  - 31.2.1.1. Ultrasound
  - 31.2.1.2. Computed tomography (CT)
  - 31.2.1.3. Magnetic resonance imaging (MRI)
  - 31.2.1.4. Others
- 31.2.2. Blood tests
  - 31.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 31.2.2.2. Liver function tests (LFTs)
  - 31.2.2.3. Blood clotting tests
  - 31.2.2.4. Others
- 31.2.3. Biopsy
  - 31.2.3.1. Needle biopsy
  - 31.2.3.2. Laparoscopic biopsy
  - 31.2.3.3. Surgical biopsy
- 31.2.4. Genetic Biomarkers
  - 31.2.4.1. miR-122 and miR-21
  - 31.2.4.2. TP53
  - 31.2.4.3. Other Genetic Biomarkers
31.3. Market Value Forecast, by Cancer Type, 2020-2035
- 31.3.1. Hepatocellular carcinoma (HCC)
- 31.3.2. Cholangiocarcinoma
- 31.3.3. Angiosarcoma of the liver
- 31.3.4. Others
31.4. Market Value Forecast, by End-user, 2020-2035
- 31.4.1. Hospital Laboratories
- 31.4.2. Diagnostic Centers
- 31.4.3. Academic and Research Institutes
- 31.4.4. Others
31.5. Market Attractiveness Analysis
- 31.5.1. By Diagnostic Test Type
- 31.5.2. By Cancer Type
- 31.5.3. By End-user

32. Mexico Liver Cancer Diagnostics Market Analysis and Forecast

32.1. Introduction
- 32.1.1. Key Findings
32.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 32.2.1. Imaging Tests
  - 32.2.1.1. Ultrasound
  - 32.2.1.2. Computed tomography (CT)
  - 32.2.1.3. Magnetic resonance imaging (MRI)
  - 32.2.1.4. Others
- 32.2.2. Blood tests
  - 32.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 32.2.2.2. Liver function tests (LFTs)
  - 32.2.2.3. Blood clotting tests
  - 32.2.2.4. Others
- 32.2.3. Biopsy
  - 32.2.3.1. Needle biopsy
  - 32.2.3.2. Laparoscopic biopsy
  - 32.2.3.3. Surgical biopsy
- 32.2.4. Genetic Biomarkers
  - 32.2.4.1. miR-122 and miR-21
  - 32.2.4.2. TP53
  - 32.2.4.3. Other Genetic Biomarkers
32.3. Market Value Forecast, by Cancer Type, 2020-2035
- 32.3.1. Hepatocellular carcinoma (HCC)
- 32.3.2. Cholangiocarcinoma
- 32.3.3. Angiosarcoma of the liver
- 32.3.4. Others
32.4. Market Value Forecast, by End-user, 2020-2035
- 32.4.1. Hospital Laboratories
- 32.4.2. Diagnostic Centers
- 32.4.3. Academic and Research Institutes
- 32.4.4. Others
32.5. Market Attractiveness Analysis
- 32.5.1. By Diagnostic Test Type
- 32.5.2. By Cancer Type
- 32.5.3. By End-user

33. Rest of Latin America Liver Cancer Diagnostics Market Analysis and Forecast

33.1. Introduction
- 33.1.1. Key Findings
33.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 33.2.1. Imaging Tests
  - 33.2.1.1. Ultrasound
  - 33.2.1.2. Computed tomography (CT)
  - 33.2.1.3. Magnetic resonance imaging (MRI)
  - 33.2.1.4. Others
- 33.2.2. Blood tests
  - 33.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 33.2.2.2. Liver function tests (LFTs)
  - 33.2.2.3. Blood clotting tests
  - 33.2.2.4. Others
- 33.2.3. Biopsy
  - 33.2.3.1. Needle biopsy
  - 33.2.3.2. Laparoscopic biopsy
  - 33.2.3.3. Surgical biopsy
- 33.2.4. Genetic Biomarkers
  - 33.2.4.1. miR-122 and miR-21
  - 33.2.4.2. TP53
  - 33.2.4.3. Other Genetic Biomarkers
33.3. Market Value Forecast, by Cancer Type, 2020-2035
- 33.3.1. Hepatocellular carcinoma (HCC)
- 33.3.2. Cholangiocarcinoma
- 33.3.3. Angiosarcoma of the liver
- 33.3.4. Others
33.4. Market Value Forecast, by End-user, 2020-2035
- 33.4.1. Hospital Laboratories
- 33.4.2. Diagnostic Centers
- 33.4.3. Academic and Research Institutes
- 33.4.4. Others
33.5. Market Attractiveness Analysis
- 33.5.1. By Diagnostic Test Type
- 33.5.2. By Cancer Type
- 33.5.3. By End-user

34. Middle East & Africa Liver Cancer Diagnostics Market Analysis and Forecast

34.1. Introduction
- 34.1.1. Key Findings
34.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 34.2.1. Imaging Tests
  - 34.2.1.1. Ultrasound
  - 34.2.1.2. Computed tomography (CT)
  - 34.2.1.3. Magnetic resonance imaging (MRI)
  - 34.2.1.4. Others
- 34.2.2. Blood tests
  - 34.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 34.2.2.2. Liver function tests (LFTs)
  - 34.2.2.3. Blood clotting tests
  - 34.2.2.4. Others
- 34.2.3. Biopsy
  - 34.2.3.1. Needle biopsy
  - 34.2.3.2. Laparoscopic biopsy
  - 34.2.3.3. Surgical biopsy
- 34.2.4. Genetic Biomarkers
  - 34.2.4.1. miR-122 and miR-21
  - 34.2.4.2. TP53
  - 34.2.4.3. Other Genetic Biomarkers
34.3. Market Value Forecast, by Cancer Type, 2020-2035
- 34.3.1. Hepatocellular carcinoma (HCC)
- 34.3.2. Cholangiocarcinoma
- 34.3.3. Angiosarcoma of the liver
- 34.3.4. Others
34.4. Market Value Forecast, by End-user, 2020-2035
- 34.4.1. Hospital Laboratories
- 34.4.2. Diagnostic Centers
- 34.4.3. Academic and Research Institutes
- 34.4.4. Others
34.5. Market Value Forecast, by Country/Sub-region, 2020-2035
- 34.5.1. GCC Countries
- 34.5.2. South Africa
- 34.5.3. Rest of Middle East & Africa
34.6. Market Attractiveness Analysis
- 34.6.1. By Diagnostic Test Type
- 34.6.2. By Cancer Type
- 34.6.3. By End-user
- 34.6.4. By Country/Sub-region

35. GCC Countries Liver Cancer Diagnostics Market Analysis and Forecast

35.1. Introduction
- 35.1.1. Key Findings
35.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 35.2.1. Imaging Tests
  - 35.2.1.1. Ultrasound
  - 35.2.1.2. Computed tomography (CT)
  - 35.2.1.3. Magnetic resonance imaging (MRI)
  - 35.2.1.4. Others
- 35.2.2. Blood tests
  - 35.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 35.2.2.2. Liver function tests (LFTs)
  - 35.2.2.3. Blood clotting tests
  - 35.2.2.4. Others
- 35.2.3. Biopsy
  - 35.2.3.1. Needle biopsy
  - 35.2.3.2. Laparoscopic biopsy
  - 35.2.3.3. Surgical biopsy
- 35.2.4. Genetic Biomarkers
  - 35.2.4.1. miR-122 and miR-21
  - 35.2.4.2. TP53
  - 35.2.4.3. Other Genetic Biomarkers
35.3. Market Value Forecast, by Cancer Type, 2020-2035
- 35.3.1. Hepatocellular carcinoma (HCC)
- 35.3.2. Cholangiocarcinoma
- 35.3.3. Angiosarcoma of the liver
- 35.3.4. Others
35.4. Market Value Forecast, by End-user, 2020-2035
- 35.4.1. Hospital Laboratories
- 35.4.2. Diagnostic Centers
- 35.4.3. Academic and Research Institutes
- 35.4.4. Others
35.5. Market Attractiveness Analysis
- 35.5.1. By Diagnostic Test Type
- 35.5.2. By Cancer Type
- 35.5.3. By End-user

36. South Africa Liver Cancer Diagnostics Market Analysis and Forecast

36.1. Introduction
- 36.1.1. Key Findings
36.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 36.2.1. Imaging Tests
  - 36.2.1.1. Ultrasound
  - 36.2.1.2. Computed tomography (CT)
  - 36.2.1.3. Magnetic resonance imaging (MRI)
  - 36.2.1.4. Others
- 36.2.2. Blood tests
  - 36.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 36.2.2.2. Liver function tests (LFTs)
  - 36.2.2.3. Blood clotting tests
  - 36.2.2.4. Others
- 36.2.3. Biopsy
  - 36.2.3.1. Needle biopsy
  - 36.2.3.2. Laparoscopic biopsy
  - 36.2.3.3. Surgical biopsy
- 36.2.4. Genetic Biomarkers
  - 36.2.4.1. miR-122 and miR-21
  - 36.2.4.2. TP53
  - 36.2.4.3. Other Genetic Biomarkers
36.3. Market Value Forecast, by Cancer Type, 2020-2035
- 36.3.1. Hepatocellular carcinoma (HCC)
- 36.3.2. Cholangiocarcinoma
- 36.3.3. Angiosarcoma of the liver
- 36.3.4. Others
36.4. Market Value Forecast, by End-user, 2020-2035
- 36.4.1. Hospital Laboratories
- 36.4.2. Diagnostic Centers
- 36.4.3. Academic and Research Institutes
- 36.4.4. Others
36.5. Market Attractiveness Analysis
- 36.5.1. By Diagnostic Test Type
- 36.5.2. By Cancer Type
- 36.5.3. By End-user

37. Rest of Middle East & Africa Liver Cancer Diagnostics Market Analysis and Forecast

37.1. Introduction
- 37.1.1. Key Findings
37.2. Market Value Forecast, by Diagnostic Test Type, 2020-2035
- 37.2.1. Imaging Tests
  - 37.2.1.1. Ultrasound
  - 37.2.1.2. Computed tomography (CT)
  - 37.2.1.3. Magnetic resonance imaging (MRI)
  - 37.2.1.4. Others
- 37.2.2. Blood tests
  - 37.2.2.1. Alpha-fetoprotein blood (AFP) test
  - 37.2.2.2. Liver function tests (LFTs)
  - 37.2.2.3. Blood clotting tests
  - 37.2.2.4. Others
- 37.2.3. Biopsy
  - 37.2.3.1. Needle biopsy
  - 37.2.3.2. Laparoscopic biopsy
  - 37.2.3.3. Surgical biopsy
- 37.2.4. Genetic Biomarkers
  - 37.2.4.1. miR-122 and miR-21
  - 37.2.4.2. TP53
  - 37.2.4.3. Other Genetic Biomarkers
37.3. Market Value Forecast, by Cancer Type, 2020-2035
- 37.3.1. Hepatocellular carcinoma (HCC)
- 37.3.2. Cholangiocarcinoma
- 37.3.3. Angiosarcoma of the liver
- 37.3.4. Others
37.4. Market Value Forecast, by End-user, 2020-2035
- 37.4.1. Hospital Laboratories
- 37.4.2. Diagnostic Centers
- 37.4.3. Academic and Research Institutes
- 37.4.4. Others
37.5. Market Attractiveness Analysis
- 37.5.1. By Diagnostic Test Type
- 37.5.2. By Cancer Type
- 37.5.3. By End-user

38. Competition Landscape

38.1. Market Player - Competition Matrix (By Tier and Size of Companies)
38.2. Market Share Analysis, by Company (2024)
38.3. Company Profiles
- 38.3.1. F. Hoffmann-La Roche Ltd
  - 38.3.1.1. Company Overview
  - 38.3.1.2. Financial Overview
  - 38.3.1.3. Product Portfolio
  - 38.3.1.4. Business Strategies
  - 38.3.1.5. Recent Developments
- 38.3.2. AdvaCare Pharma
  - 38.3.2.1. Company Overview
  - 38.3.2.2. Financial Overview
  - 38.3.2.3. Product Portfolio
  - 38.3.2.4. Business Strategies
  - 38.3.2.5. Recent Developments
- 38.3.3. Siemens Healthineers AG
  - 38.3.3.1. Company Overview
  - 38.3.3.2. Financial Overview
  - 38.3.3.3. Product Portfolio
  - 38.3.3.4. Business Strategies
  - 38.3.3.5. Recent Developments
- 38.3.4. QIAGEN
  - 38.3.4.1. Company Overview
  - 38.3.4.2. Financial Overview
  - 38.3.4.3. Product Portfolio
  - 38.3.4.4. Business Strategies
  - 38.3.4.5. Recent Developments
- 38.3.5. Bio-Rad Laboratories, Inc.
  - 38.3.5.1. Company Overview
  - 38.3.5.2. Financial Overview
  - 38.3.5.3. Product Portfolio
  - 38.3.5.4. Business Strategies
  - 38.3.5.5. Recent Developments
- 38.3.6. Agilent Technologies Inc.
  - 38.3.6.1. Company Overview
  - 38.3.6.2. Financial Overview
  - 38.3.6.3. Product Portfolio
  - 38.3.6.4. Business Strategies
  - 38.3.6.5. Recent Developments
- 38.3.7. Atlas Medical GmbH
  - 38.3.7.1. Company Overview
  - 38.3.7.2. Financial Overview
  - 38.3.7.3. Product Portfolio
  - 38.3.7.4. Business Strategies
  - 38.3.7.5. Recent Developments
- 38.3.8. Epigenomics AG
  - 38.3.8.1. Company Overview
  - 38.3.8.2. Financial Overview
  - 38.3.8.3. Product Portfolio
  - 38.3.8.4. Business Strategies
  - 38.3.8.5. Recent Developments
- 38.3.9. GE HealthCare
  - 38.3.9.1. Company Overview
  - 38.3.9.2. Financial Overview
  - 38.3.9.3. Product Portfolio
  - 38.3.9.4. Business Strategies
  - 38.3.9.5. Recent Developments
- 38.3.10. Koninklijke Philips N.V
  - 38.3.10.1. Company Overview
  - 38.3.10.2. Financial Overview
  - 38.3.10.3. Product Portfolio
  - 38.3.10.4. Business Strategies
  - 38.3.10.5. Recent Developments
- 38.3.11. CANON MEDICAL SYSTEMS CORPORATION
  - 38.3.11.1. Company Overview
  - 38.3.11.2. Financial Overview
  - 38.3.11.3. Product Portfolio
  - 38.3.11.4. Business Strategies
  - 38.3.11.5. Recent Developments
- 38.3.12. Samsung Medison Co., Ltd.
  - 38.3.12.1. Company Overview
  - 38.3.12.2. Financial Overview
  - 38.3.12.3. Product Portfolio
  - 38.3.12.4. Business Strategies
  - 38.3.12.5. Recent Developments
- 38.3.13. Hipro Biotechnology Co.,Ltd.
  - 38.3.13.1. Company Overview
  - 38.3.13.2. Financial Overview
  - 38.3.13.3. Product Portfolio
  - 38.3.13.4. Business Strategies
  - 38.3.13.5. Recent Developments
- 38.3.14. Mursla Ltd. / Mursla Inc.
  - 38.3.14.1. Company Overview
  - 38.3.14.2. Financial Overview
  - 38.3.14.3. Product Portfolio
  - 38.3.14.4. Business Strategies
  - 38.3.14.5. Recent Developments
- 38.3.15. Exact Sciences Corporation
  - 38.3.15.1. Company Overview
  - 38.3.15.2. Financial Overview
  - 38.3.15.3. Product Portfolio
  - 38.3.15.4. Business Strategies
  - 38.3.15.5. Recent Developments
- 38.3.16. Helio Genomics
  - 38.3.16.1. Company Overview
  - 38.3.16.2. Financial Overview
  - 38.3.16.3. Product Portfolio
  - 38.3.16.4. Business Strategies
  - 38.3.16.5. Recent Developments
- 38.3.17. Other Prominent Players
  - 38.3.17.1. Company Overview
  - 38.3.17.2. Financial Overview
  - 38.3.17.3. Product Portfolio
  - 38.3.17.4. Business Strategies
  - 38.3.17.5. Recent Developments

Product Code: 61431

List of Tables

Table 01: Global Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 02: Global Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 03: Global Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 04: Global Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 05: Global Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 06: Global Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 07: Global Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 08: Global Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Region, 2020 to 2035
Table 09: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country, 2020-2035
Table 10: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 11: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 12: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 13: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 14: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 15: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 16: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 17: U.S. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 18: U.S. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 19: U.S. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 20: U.S. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 21: U.S. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 22: U.S. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 23: U.S. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 24: Canada Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 25: Canada Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 26: Canada Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 27: Canada Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 28: Canada Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 29: Canada Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 30: Canada Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 31: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2035
Table 32: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 33: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 34: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 35: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 36: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 37: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 38: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 39: Germany Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 40: Germany Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 41: Germany Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 42: Germany Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 43: Germany Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 44: Germany Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 45: Germany Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 46: U.K. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 47: U.K. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 48: U.K. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 49: U.K. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 50: U.K. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 51: U.K. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 52: U.K. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 53: France Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 54: France Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 55: France Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 56: France Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 57: France Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 58: France Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 59: France Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 60: Italy Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 61: Italy Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 62: Italy Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 63: Italy Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 64: Italy Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 65: Italy Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 66: Italy Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 67: Spain Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 68: Spain Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 69: Spain Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 70: Spain Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 71: Spain Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 72: Spain Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 73: Spain Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 74: Switzerland Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 75: Switzerland Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 76: Switzerland Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 77: Switzerland Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 78: Switzerland Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 79: Switzerland Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 80: Switzerland Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 81: The Netherlands Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 82: The Netherlands Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 83: The Netherlands Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 84: The Netherlands Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 85: The Netherlands Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 86: The Netherlands Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 87: The Netherlands Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 88: Rest of Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 89: Rest of Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 90: Rest of Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 91: Rest of Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 92: Rest of Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 93: Rest of Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 94: Rest of Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 95: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2035
Table 96: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 97: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 98: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 99: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 100: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 101: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 102: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 103: China Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 104: China Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 105: China Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 106: China Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 107: China Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 108: China Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 109: China Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 110: India Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 111: India Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 112: India Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 113: India Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 114: India Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 115: India Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 116: India Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 117: Japan Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 118: Japan Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 119: Japan Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 120: Japan Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 121: Japan Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 122: Japan Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 123: Japan Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 124: South Korea Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 125: South Korea Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 126: South Korea Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 127: South Korea Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 128: South Korea Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 129: South Korea Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 130: South Korea Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 131: Australia & New Zealand Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 132: Australia & New Zealand Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 133: Australia & New Zealand Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 134: Australia & New Zealand Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 135: Australia & New Zealand Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 136: Australia & New Zealand Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 137: Australia & New Zealand Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 138: Rest of Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 139: Rest of Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 140: Rest of Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 141: Rest of Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 142: Rest of Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 143: Rest of Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 144: Rest of Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 145: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2035
Table 146: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 147: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 148: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 149: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 150: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 151: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 152: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 153: Brazil Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 154: Brazil Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 155: Brazil Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 156: Brazil Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 157: Brazil Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 158: Brazil Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 159: Brazil Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 160: Mexico Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 161: Mexico Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 162: Mexico Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 163: Mexico Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 164: Mexico Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 165: Mexico Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 166: Mexico Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 167: Argentina Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 168: Argentina Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 169: Argentina Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 170: Argentina Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 171: Argentina Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 172: Argentina Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 173: Argentina Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 174: Rest of Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 175: Rest of Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 176: Rest of Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 177: Rest of Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 178: Rest of Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 179: Rest of Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 180: Rest of Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 181: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2035
Table 182: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 183: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 184: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 185: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 186: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 187: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 188: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 189: GCC Countries Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 190: GCC Countries Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 191: GCC Countries Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 192: GCC Countries Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 193: GCC Countries Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 194: GCC Countries Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 195: GCC Countries Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 196: South Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 197: South Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 198: South Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 199: South Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 200: South Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 201: South Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 202: South Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 203: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 204: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 205: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 206: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 207: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 208: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 209: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035

List of Figures

Figure 01: Global Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 02: Global Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 03: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Imaging Tests, 2020 to 2035
Figure 04: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Blood Tests, 2020 to 2035
Figure 05: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Biopsy, 2020 to 2035
Figure 06: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Genetic Biomarkers, 2020 to 2035
Figure 07: Global Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 08: Global Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 09: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Hepatocellular carcinoma (HCC), 2020 to 2035
Figure 10: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Cholangiocarcinoma, 2020 to 2035
Figure 11: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Angiosarcoma of the liver, 2020 to 2035
Figure 12: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 13: Global Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 14: Global Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 15: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Hospital Laboratories, 2020 to 2035
Figure 16: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Diagnostic Centers, 2020 to 2035
Figure 17: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Academic and Research Institutes, 2020 to 2035
Figure 18: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 19: Global Liver Cancer Diagnostics Market Value Share Analysis, By Region, 2024 and 2035
Figure 20: Global Liver Cancer Diagnostics Market Attractiveness Analysis, By Region, 2025 to 2035
Figure 21: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 22: North America Liver Cancer Diagnostics Market Value Share Analysis, by Country, 2024 and 2035
Figure 23: North America Liver Cancer Diagnostics Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 24: North America Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 25: North America Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 26: North America Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 27: North America Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 28: North America Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 29: North America Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 30: U.S. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 31: U.S. Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 32: U.S. Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 33: U.S. Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 34: U.S. Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 35: U.S. Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 36: U.S. Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 37: Canada Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 38: Canada Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 39: Canada Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 40: Canada Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 41: Canada Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 42: Canada Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 43: Canada Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 44: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 45: Europe Liver Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 46: Europe Liver Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 47: Europe Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 48: Europe Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 49: Europe Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 50: Europe Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 51: Europe Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 52: Europe Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 53: Germany Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 54: Germany Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 55: Germany Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 56: Germany Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 57: Germany Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 58: Germany Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 59: Germany Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 60: U.K. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 61: U.K. Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 62: U.K. Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 63: U.K. Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 64: U.K. Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 65: U.K. Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 66: U.K. Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 67: France Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 68: France Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 69: France Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 70: France Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 71: France Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 72: France Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 73: France Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 74: Italy Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 75: Italy Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 76: Italy Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 77: Italy Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 78: Italy Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 79: Italy Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 80: Italy Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 81: Spain Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 82: Spain Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 83: Spain Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 84: Spain Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 85: Spain Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 86: Spain Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 87: Spain Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 88: Switzerland Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 89: Switzerland Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 90: Switzerland Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 91: Switzerland Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 92: Switzerland Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 93: Switzerland Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 94: Switzerland Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 95: The Netherlands Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 96: The Netherlands Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 97: The Netherlands Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 98: The Netherlands Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 99: The Netherlands Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 100: The Netherlands Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 101: The Netherlands Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 102: Rest of Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 103: Rest of Europe Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 104: Rest of Europe Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 105: Rest of Europe Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 106: Rest of Europe Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 107: Rest of Europe Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 108: Rest of Europe Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 109: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 110: Asia Pacific Liver Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 111: Asia Pacific Liver Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 112: Asia Pacific Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 113: Asia Pacific Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 114: Asia Pacific Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 115: Asia Pacific Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 116: Asia Pacific Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 117: Asia Pacific Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 118: China Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 119: China Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 120: China Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 121: China Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 122: China Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 123: China Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 124: China Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 125: India Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 126: India Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 127: India Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 128: India Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 129: India Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 130: India Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 131: India Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 132: Japan Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 133: Japan Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 134: Japan Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 135: Japan Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 136: Japan Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 137: Japan Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 138: Japan Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 139: South Korea Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 140: South Korea Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 141: South Korea Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 142: South Korea Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 143: South Korea Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 144: South Korea Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 145: South Korea Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 146: Australia & New Zealand Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 147: Australia & New Zealand Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 148: Australia & New Zealand Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 149: Australia & New Zealand Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 150: Australia & New Zealand Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 151: Australia & New Zealand Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 152: Australia & New Zealand Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 153: Rest of Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 154: Rest of Asia Pacific Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 155: Rest of Asia Pacific Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 156: Rest of Asia Pacific Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 157: Rest of Asia Pacific Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 158: Rest of Asia Pacific Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 159: Rest of Asia Pacific Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 160: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 161: Latin America Liver Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 162: Latin America Liver Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 163: Latin America Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 164: Latin America Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 165: Latin America Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 166: Latin America Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 167: Latin America Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 168: Latin America Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 169: Brazil Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 170: Brazil Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 171: Brazil Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 172: Brazil Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 173: Brazil Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 174: Brazil Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 175: Brazil Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 176: Mexico Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 177: Mexico Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 178: Mexico Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 179: Mexico Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 180: Mexico Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 181: Mexico Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 182: Mexico Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 183: Argentina Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 184: Argentina Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 185: Argentina Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 186: Argentina Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 187: Argentina Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 188: Argentina Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 189: Argentina Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 190: Rest of Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 191: Rest of Latin America Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 192: Rest of Latin America Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 193: Rest of Latin America Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 194: Rest of Latin America Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 195: Rest of Latin America Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 196: Rest of Latin America Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 197: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 198: Middle East & Africa Liver Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 199: Middle East & Africa Liver Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 200: Middle East & Africa Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 201: Middle East & Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 202: Middle East & Africa Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 203: Middle East & Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 204: Middle East & Africa Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 205: Middle East & Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 206: GCC Countries Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 207: GCC Countries Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 208: GCC Countries Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 209: GCC Countries Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 210: GCC Countries Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 211: GCC Countries Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 212: GCC Countries Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 213: South Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 214: South Africa Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 215: South Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 216: South Africa Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 217: South Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 218: South Africa Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 219: South Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 220: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 221: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 222: Rest of Middle East & Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 223: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 224: Rest of Middle East & Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 225: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 226: Rest of Middle East & Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035

Liver Cancer Diagnostics Market

Description

Table of Contents

List of Tables

Liver Cancer Diagnostics Market - Scope of Report

Key Questions Answered in Global Liver Cancer Diagnostics Market Report:

Global Liver Cancer Diagnostics Market - Research Objectives and Research Approach

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global Liver Cancer Diagnostics Market

4. Market Overview

5. Key Insights

6. Global Liver Cancer Diagnostics Market Analysis and Forecast, by Diagnostic Test Type

7. Global Liver Cancer Diagnostics Market Analysis and Forecast, by Cancer Type

8. Global Liver Cancer Diagnostics Market Analysis and Forecast, by End-user

9. Global Liver Cancer Diagnostics Market Analysis and Forecast, by Region

10. North America Liver Cancer Diagnostics Market Analysis and Forecast

11. U.S. Liver Cancer Diagnostics Market Analysis and Forecast

12. Canada Liver Cancer Diagnostics Market Analysis and Forecast

13. Europe Liver Cancer Diagnostics Market Analysis and Forecast

14. Germany Liver Cancer Diagnostics Market Analysis and Forecast

15. UK Liver Cancer Diagnostics Market Analysis and Forecast

16. France Liver Cancer Diagnostics Market Analysis and Forecast

17. Italy Liver Cancer Diagnostics Market Analysis and Forecast

18. Spain Liver Cancer Diagnostics Market Analysis and Forecast

19. The Netherlands Liver Cancer Diagnostics Market Analysis and Forecast

20. Rest of Europe Liver Cancer Diagnostics Market Analysis and Forecast

21. Asia Pacific Liver Cancer Diagnostics Market Analysis and Forecast

22. China Liver Cancer Diagnostics Market Analysis and Forecast

23. India Liver Cancer Diagnostics Market Analysis and Forecast

24. Japan Liver Cancer Diagnostics Market Analysis and Forecast

25. South Korea Liver Cancer Diagnostics Market Analysis and Forecast

26. Australia & New Zealand Liver Cancer Diagnostics Market Analysis and Forecast

27. ASEAN Liver Cancer Diagnostics Market Analysis and Forecast

28. Rest of Asia Pacific Liver Cancer Diagnostics Market Analysis and Forecast

29. Latin America Liver Cancer Diagnostics Market Analysis and Forecast

30. Brazil Liver Cancer Diagnostics Market Analysis and Forecast

31. Argentina Liver Cancer Diagnostics Market Analysis and Forecast

32. Mexico Liver Cancer Diagnostics Market Analysis and Forecast

33. Rest of Latin America Liver Cancer Diagnostics Market Analysis and Forecast

34. Middle East & Africa Liver Cancer Diagnostics Market Analysis and Forecast

35. GCC Countries Liver Cancer Diagnostics Market Analysis and Forecast

36. South Africa Liver Cancer Diagnostics Market Analysis and Forecast

37. Rest of Middle East & Africa Liver Cancer Diagnostics Market Analysis and Forecast

38. Competition Landscape

List of Tables

List of Figures